See more : Q.E.P. Co., Inc. (QEPC) Income Statement Analysis – Financial Results
Complete financial analysis of SK Biopharmaceuticals Co., Ltd. (326030.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SK Biopharmaceuticals Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Morganite Crucible (India) Limited (MORGANITE.BO) Income Statement Analysis – Financial Results
- Metal Sky Star Acquisition Corporation (MSSAU) Income Statement Analysis – Financial Results
- TopBuild Corp. (BLD) Income Statement Analysis – Financial Results
- TeamViewer AG (TMV.DE) Income Statement Analysis – Financial Results
- Logo Yazilim Sanayi ve Ticaret A.S. (LOGO.IS) Income Statement Analysis – Financial Results
SK Biopharmaceuticals Co., Ltd. (326030.KS)
About SK Biopharmaceuticals Co., Ltd.
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders. The company is developing Cenobamate for the treatment of epilepsy; Solriamfetol for the treatment of excessive daytime sleepiness in narcolepsy or obstructive sleep apneal; Carisbamate that is in Phase 1b/2 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials to treat rare neurological disease. It is also developing SKL13865 that is in Phase 1 clinical trials to treat attention deficit/hyperactivity disorder; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder; and SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy. The company was founded in 2011 and is headquartered in Seongnam, South Korea. SK Biopharmaceuticals Co., Ltd. operates as subsidiary of SK Inc.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 354.89B | 246.18B | 418.64B | 26.00B | 123.85B | 1.10B | 85.32B | 89.93B | 71.42B | 72.44B | 60.45B | 51.80B | 37.63B |
| Cost of Revenue | 46.52B | 37.77B | 22.34B | 1.97B | 514.20M | 3.34B | 81.74B | 78.85B | 45.69B | 46.58B | 44.40B | 37.67B | 27.40B |
| Gross Profit | 308.37B | 208.41B | 396.31B | 24.03B | 123.34B | -2.24B | 3.57B | 11.07B | 25.72B | 25.86B | 16.06B | 14.13B | 10.23B |
| Gross Profit Ratio | 86.89% | 84.66% | 94.66% | 92.41% | 99.58% | -204.19% | 4.19% | 12.31% | 36.02% | 35.70% | 26.56% | 27.27% | 27.19% |
| Research & Development | 137.70B | 122.82B | 114.53B | 108.44B | 176.21B | 121.29B | 85.60B | 53.54B | 56.62B | 54.39B | 49.79B | 35.07B | 22.93B |
| General & Administrative | 61.73B | 62.44B | 49.96B | 53.73B | 9.07B | 8.94B | 3.89B | 3.08B | 3.72B | 1.96B | 2.16B | 2.76B | 2.67B |
| Selling & Marketing | 40.14B | 49.89B | 39.84B | 25.36B | 488.74M | 227.03M | 875.93M | 1.25B | 1.29B | 866.32M | 1.07B | 1.06B | 753.52M |
| SG&A | 204.31B | 112.32B | 89.80B | 79.10B | 9.56B | 9.17B | 4.77B | 4.33B | 5.01B | 2.83B | 3.23B | 3.82B | 3.42B |
| Other Expenses | 0.00 | 104.35B | 97.02B | 75.99B | 16.83B | 380.49M | -157.55M | -277.76M | 82.99M | -249.02M | -1.16B | 899.51M | 4.32B |
| Operating Expenses | 358.33B | 339.49B | 301.35B | 263.52B | 202.60B | 140.20B | 101.54B | 68.75B | 65.17B | 65.10B | 60.22B | 50.12B | 30.67B |
| Cost & Expenses | 392.99B | 377.26B | 323.69B | 265.50B | 203.11B | 140.20B | 183.29B | 147.60B | 110.86B | 111.68B | 104.61B | 87.79B | 58.07B |
| Interest Income | 9.32B | 6.75B | 2.34B | 2.12B | 1.78B | 1.74B | 1.43B | 2.27B | 2.13B | 3.47B | 2.29B | 4.26B | 3.79B |
| Interest Expense | 8.28B | 3.72B | 946.98M | 4.46B | 1.55B | 31.49M | 30.95M | 23.59M | 38.00K | 217.00K | 680.00 | 1.96M | 218.18M |
| Depreciation & Amortization | 15.32B | 12.98B | 11.64B | 10.86B | 6.50B | 3.34B | 3.17B | 3.09B | 4.57B | 4.34B | 5.25B | 5.76B | 5.17B |
| EBITDA | -22.20B | -125.77B | 106.60B | -224.59B | -73.98B | -134.26B | -95.77B | -54.59B | -31.56B | -31.90B | -38.91B | -24.20B | -15.30B |
| EBITDA Ratio | -6.26% | -45.95% | 20.52% | -871.31% | -59.73% | -12,181.36% | -109.67% | -29.18% | -44.20% | -42.96% | -61.90% | -43.53% | -29.39% |
| Operating Income | -37.52B | -131.08B | 74.25B | -239.50B | -79.26B | -139.10B | -97.97B | -57.67B | -39.44B | -39.24B | -44.16B | -35.99B | -24.31B |
| Operating Income Ratio | -10.57% | -53.24% | 17.74% | -921.18% | -63.99% | -12,660.28% | -114.84% | -64.13% | -55.23% | -54.17% | -73.04% | -69.48% | -64.59% |
| Total Other Income/Expenses | -6.34B | -11.39B | -23.68B | -410.51M | -5.19B | 1.46B | -932.19M | 27.31B | 13.56B | 3.00B | 1.60B | 6.03B | 3.62B |
| Income Before Tax | -43.86B | -142.47B | 71.28B | -239.91B | -84.45B | -137.64B | -96.81B | -30.36B | -25.79B | -36.24B | -42.55B | -29.96B | -20.69B |
| Income Before Tax Ratio | -12.36% | -57.87% | 17.03% | -922.76% | -68.19% | -12,526.99% | -113.47% | -33.76% | -36.11% | -50.02% | -70.39% | -57.83% | -54.98% |
| Income Tax Expense | -8.48B | -3.04B | 6.43B | 7.50B | -12.93B | 583.20M | 839.58M | 28.35B | 2.27B | 810.56M | -1.55B | 373.90M | -1.23B |
| Net Income | -32.88B | -139.43B | 64.85B | -247.41B | -71.52B | -138.10B | -97.65B | -30.36B | -28.06B | -37.05B | -41.00B | -30.33B | -19.47B |
| Net Income Ratio | -9.27% | -56.64% | 15.49% | -951.63% | -57.75% | -12,568.64% | -114.46% | -33.76% | -39.29% | -51.14% | -67.82% | -58.56% | -51.73% |
| EPS | -419.89 | -1.78K | 828.03 | -3.45K | -3.65K | -2.22K | -1.95K | -607.00 | -561.25 | -749.00 | -1.03K | -758.00 | -487.00 |
| EPS Diluted | -419.89 | -1.78K | 828.03 | -3.45K | -3.65K | -2.22K | -1.95K | -607.00 | -561.25 | -749.00 | -1.03K | -758.00 | -487.00 |
| Weighted Avg Shares Out | 78.31M | 78.31M | 78.31M | 71.77M | 19.58M | 62.23M | 50.00M | 50.02M | 50.00M | 49.46M | 40.00M | 40.01M | 39.97M |
| Weighted Avg Shares Out (Dil) | 78.31M | 78.31M | 78.31M | 71.77M | 19.58M | 62.23M | 50.00M | 50.02M | 50.00M | 49.46M | 40.00M | 40.01M | 39.97M |
Source: https://incomestatements.info
Category: Stock Reports